Assertio Holdings, Inc. (ASRT) Stock Price & Analysis
Assertio Holdings, Inc. (ASRT) rose 0.13% to USD 23.46 as of June 10, 2026 at 10:33 UTC, according to Nexqual real-time market data.
ASRT last closed at USD 23.43; the session ranged USD 23.43–23.47 on volume of 546,477 shares. Market capitalization is $151.60M, with a 52-week range of USD 8.61–23.47 (NCM). Source: Nexqual, June 10, 2026 at 10:33 UTC.
Key Statistics (as of June 10, 2026 at 10:33 UTC)
| Price | USD 23.46 |
|---|---|
| Change | ▲ 0.13% (up) |
| Previous Close | USD 23.43 |
| Open | USD 23.44 |
| Day Range | USD 23.43 – 23.47 |
| 52-Week Range | USD 8.61 – 23.47 |
| Volume | 546,477 shares |
| Market Cap | $151.60M |
| Exchange | NCM |
Technical Analysis (ASRT)
Nexqual's technical model rates ASRT "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 10:33 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 91.56 (overbought) |
| vs SMA50 | Above (USD 20.73) |
| MACD | 0.87 (positive) |
Analyst Ratings (ASRT)
Wall Street analysts rate ASRT "None" based on 3 analysts, with a mean price target of USD 24.43 (range USD 21.8–28), per Nexqual as of June 10, 2026 at 10:33 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 24.43 |
| High Target | USD 28 |
| Low Target | USD 21.8 |
| Buy / Hold / Sell | 1 / 3 / 0 |
Earnings (ASRT)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -1.1 |
| Revenue Estimate | $27.66M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -1.06 vs est -1.8 ▲ beat |
| 2025-09-30 | USD 2.7 vs est 0 ▲ beat |
| 2025-06-30 | USD 0.3 vs est -0.08 ▲ beat |
Source: Nexqual, June 10, 2026 at 10:33 UTC.
Financials & Fundamentals (ASRT)
| Total Revenue | $102.16M |
|---|---|
| Revenue Growth (YoY) | -62.50% |
| Gross Margin | +70.33% |
| Operating Margin | -185.95% |
| Profit Margin | -34.94% |
| ROE | -38.76% |
| Debt / Equity | 53.3 |
| Current Ratio | 1.82 |
| Total Cash | $71.57M |
| Total Debt | $40.31M |
| Free Cash Flow | $7.75M |
Source: Nexqual, June 10, 2026 at 10:33 UTC.
Financial Health Score (ASRT)
Nexqual rates Assertio Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:33 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $72M cash vs $40M debt, net cash position |
| Cash Flow | Solid — FCF $8M, 7% margin |
| Efficiency | Critical — ROE -39%, ROA -5.7% |
Ownership (ASRT)
| Insider Ownership | +1.97% |
|---|---|
| Institutional Ownership | +29.30% |
| Shares Outstanding | 6.46M |
| Float | 6.26M |
| Short % of Float | +5.25% |
Source: Nexqual, June 10, 2026 at 10:33 UTC.
Leadership (ASRT)
Assertio Holdings, Inc. is led by Mark L. Reisenauer (age 59), CEO & Director, per Nexqual as of June 10, 2026 at 10:33 UTC.
| CEO & Director | Mark L. Reisenauer (age 59) |
|---|---|
| President & COO | Paul Schwichtenberg (age 54) |
| Executive VP & CFO | Ajay Patel (age 41) |
| Senior Vice President of Medical | Howard J. Franklin |
Major Backers & Investors (ASRT)
Notable institutional backers of Assertio Holdings, Inc. include Nantahala Capital Management, LLC, Opaleye Management Inc., Renaissance Technologies, according to Nexqual as of June 10, 2026 at 10:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Nantahala Capital Management, LLC | 10.71% |
| Opaleye Management Inc. | 4.11% |
| Renaissance Technologies | 3.54% |
| Edgewood Management Llc | 1.66% |
| Jane Street Group, LLC | 1.23% |
| Walleye Capital LLC | 1.02% |
| Fidelity | 0.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.26% |
| BlackRock | 1.39% |
| Geode Capital | 1.18% |
Source: Nexqual, June 10, 2026 at 10:33 UTC.
From Assertio Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services, the FDA, and the DOJ all actively enforce laws and regulations prohibiting promotion of off-label use and the promotion of products for which marketing clearance has not been obtained.
- Most of our principal competitors have substantially greater financial, sales, marketing, personnel and research and development resources than we and our commercial partners do. 24 ROLVEDON is a novel long-acting G-CSF that employs a proprietary technology that is designed to prolong the duration of biologics, reducing the frequency of administration.
- We seek to protect such information, in part, by entering into confidentiality agreements with employees, consultants, collaborative partners and others before such persons or entities have access to our proprietary trade secrets and know-how.
Partnerships
- Our current and any future commercialization, collaborative or licensing partners may pursue existing or other development-stage products or alternative technologies in preference to those being commercialized or developed in collaboration with us.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTXR | Citius Pharmaceuticals, Inc. | USD 0.56 | ▼ 0.73% |
| VYNE | VYNE Therapeutics Inc. | USD 0.67 | ▲ 2.24% |
| CTRM | Castor Maritime Inc. | USD 2.18 | ▲ 2.35% |
| ITRMF | Iterum Therapeutics plc | USD 0.05 | ▲ 0% |
| ATOS | Atossa Therapeutics, Inc. | USD 4.41 | ▼ 1.34% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:33 UTC. This page is informational and not investment advice.